https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51652 Wed 13 Sep 2023 10:00:03 AEST ]]> The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38113 Wed 04 Aug 2021 11:40:28 AEST ]]> Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> Multiple Sclerosis Relapses Following Cessation of Fingolimod https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> Delay from treatment start to full effect of immunotherapies for multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39111 Tue 21 Mar 2023 17:45:24 AEDT ]]> Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> Comparative effectiveness in multiple sclerosis: A methodological comparison https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51450 Tue 05 Sep 2023 17:56:18 AEST ]]> Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52120 Thu 28 Sep 2023 15:04:45 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Prediction of multiple sclerosis outcomes when switching to ocrelizumab https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> Confirmed disability progression as a marker of permanent disability in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> Determinants of therapeutic lag in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> Predictors of treatment switching in the Big Multiple Sclerosis Data Network https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53931 Fri 22 Mar 2024 08:23:10 AEDT ]]> Prediction of relapse activity when switching to cladribine for multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51076 Fri 18 Aug 2023 09:03:23 AEST ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>